Podcasts

E-Books

Videos

Articles

Clinical

Tony Hagen is senior managing editor for The Center for Biosimilars

Investigators produced what they described as the first evidence supporting the use of biosimilar erythropoiesis-stimulating agents (ESAs) in patients with myelofibrosis-related anemia.

Biosimilar ESA Is Effective in Myelofibrosis Anemia

Skylar Jeremias is the Managing Editor for The Center for Biosimilars and The American Journal of Managed Care (AJMC).

Canada Health has approved the launch of Sandoz' pegfilgrastim and rituximab biosimilars.
 

Sandoz Gets Canada's Nod to Launch Ziextenzo, Riximyo

Isha Bangia, PharmD, MBA, is a manager of US market access at Certara Evidence & Access. She received her PharmD from Rutgers University and an MBA from Johns Hopkins University. Her current responsibilities include optimizing product value stories and working with customers to improve access across the US healthcare system. Her experience includes practicing pharmacy, payer market research, and pharma strategy and analytics. Her work has covered many therapeutic areas, including biosimilars, oncology, diabetes, vaccines, and rare diseases.

Biosimilar discounts to reference products have improved over time, but they are deeper in some categories than others.
 

Biosimilar Discounts Vary by Category 

As part of pilot program designed to improve access to cheaper medications in oncology, a rituximab biosimilar from Celltrion has been approved for use by the World Health Organization (WHO).

WHO Clears Celltrion Rituximab for Use

Recognizing that oncology practices are struggling with the pandemic, the Center for Medicare and Medicaid Innovation has eased some performance requirements.
 

Timeline Is Extended for Practices Struggling With COVID-19

Here is a summary of our coverage from ASCO20 Virtual, the annual meeting for the American Society of Clinical Oncology (ASCO).

ASCO20 Virtual Biosimilars Roundup

Clinical trials leading up to biosimilar approval may not reveal the full safety and efficacy profile of biosimilars vs reference products, and postmarketing studies may be essential to elucidate any differences, investigators said.

Clinically Meaningful Differences Under the Microscope

A real-world study helped show how pegfilgrastim biosimilar can improve savings in the Oncology Care Model and its successor, the Oncology Care First Model, according to findings presented at ASCO20 Virtual, the annual meeting of the American Society of Clinical Oncology.

More Savings Are Possible for Oncology Care Model, ASCO Study Says

Switching patients with cancer to biosimilar pegfilgrastim for prophylaxis treatment of chemotherapy-induced febrile neutropenia could generate significant savings for adjuvant treatment, investigators found in studies presented at ASCO20 Virtual, the annual meeting of the American Society of Clinical Oncology (ASCO).
 

Biosimilar Pegfilgrastim Savings Aid More Patients in Models Presented at ASCO

Shanghai Henlius Biotech received a positive European review opinion for its trastuzumab biosimilar HLXO2 and anticipates marketing authorization in 2 to 3 months.
 

Oncology